473 related articles for article (PubMed ID: 22735971)
1. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-based therapies in cancer: advances and challenges.
Sapra P; Shor B
Pharmacol Ther; 2013 Jun; 138(3):452-69. PubMed ID: 23507041
[TBL] [Abstract][Full Text] [Related]
3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
4. Antibody drug conjugates - Trojan horses in the war on cancer.
Iyer U; Kadambi VJ
J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
[TBL] [Abstract][Full Text] [Related]
5. Drug-conjugated monoclonal antibodies for the treatment of cancer.
Lambert JM
Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
[TBL] [Abstract][Full Text] [Related]
6. [Antibody-drug conjugates and their application in the treatment of hematological malignancies].
Lin L; Ding Q; Tang Q; Zhang ZZ; Dai Z; Zhan JB
Yao Xue Xue Bao; 2012 Oct; 47(10):1287-96. PubMed ID: 23289140
[TBL] [Abstract][Full Text] [Related]
7. Antibody conjugates and therapeutic strategies.
McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
[TBL] [Abstract][Full Text] [Related]
8. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
9. Antibody-cytotoxic agent conjugates for cancer therapy.
Chen J; Jaracz S; Zhao X; Chen S; Ojima I
Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
Dosio F; Brusa P; Cattel L
Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744
[TBL] [Abstract][Full Text] [Related]
11. Investigational antibody drug conjugates for solid tumors.
Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
[TBL] [Abstract][Full Text] [Related]
12. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
13. [Immunoconjugates, drug-armed antibodies to fight against cancer].
Haeuw JF; Caussanel V; Beck A
Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
[TBL] [Abstract][Full Text] [Related]
14. Antibody conjugate therapeutics: challenges and potential.
Teicher BA; Chari RV
Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
[TBL] [Abstract][Full Text] [Related]
15. [Targeting of antitumor drugs with monoclonal antibodies].
Monneret C; Florent JC
Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
[TBL] [Abstract][Full Text] [Related]
16. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
17. The next generation of antibody-drug conjugates comes of age.
Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates as targeted cancer therapeutics.
Sun Y; Yu F; Sun BW
Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167
[TBL] [Abstract][Full Text] [Related]
20. [An overview of antibody-based cancer therapy].
Miao QF; Shao RG; Zhen YS
Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
